Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | RARB | P10826 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196110 | 0.84 | PKM (0.88) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL3152149 | 0.84 | CA1 (0.52) | PKMMAPK1TSHRTP53ESR1 | |
| SCHEMBL16418454 | 0.82 | ESR1 (0.66) | ESR1L3MBTL1 | |
| SCHEMBL3138707 | 0.82 | MAPT (0.77) | ESR1L3MBTL1 | |
| SCHEMBL118037 | 0.82 | PKM (0.77) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL1952122 | 0.82 | TP53 (0.79) | PKMMAPK1TSHRTP53PLA2G4B | |
| Bromide SCHEMBL16414995 | 0.81 | ESR1 (0.64) | ESR1L3MBTL1 | |
| SCHEMBL736876 | 0.81 | TP53 (0.89) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL175191 | 0.81 | TP53 (0.77) | PKMMAPK1TSHRTP53PLA2G4B | |
| SCHEMBL10798086 | 0.81 | TP53 (0.89) | PKMMAPK1TSHRTP53PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687546-B2 | Quaternary ammonium compound, process for producing the same, therapeutic agent for cerebrovascular disorder, and therapeutic agent for heart disease | ACTIVUS PHARMA CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080269345-A1 | Quarternary Ammonium Compound, Process for Producing the Same, Therapeutic Agent for Cerebrovascular Disorder, and Therapeutic Agent for Heart Disease | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269345-A1 | Quarternary Ammonium Compound, Process for Producing the Same, Therapeutic Agent for Cerebrovascular Disorder, and Therapeutic Agent for Heart Disease | HRH4, KCNH3, ARGLU1 | PKM 2437/4885MAPK1 2873/4885TSHR 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.